Prescription of Intravenous Medication for Blocking Heroin or Morphine Intoxication Path and Using Thereof

ABSTRACT

Disclosed are a prescription of intravenous medication for blocking a heroin or morphine intoxication path and its using. The prescription of intravenous infusion includes Cerebrolysin, Piracetam, Cimetidine, Scopolamine Butylbromide, Nefopam, B.C Complex, Vitamin B1, Ascorbic Acid, Ketorolac, Guronsan, Hyoscine Butylbromide and Sukerin. The prescription activates a patient&#39;s liver and circulatory system to block drug intoxication. The using for blocking drugs includes an acute withdrawal part, wherein the prescription of intravenous infusion is injected and the timing of drug administration and the safe dosage are controlled according to clinical symptoms, and an appropriate amount of a supplementary medicine such as Haloperidol is added, and the processes of detoxication, relieving symptoms, suppressing restlessness, and sobering are conducted to block acute withdrawal symptoms of an acute withdrawal addict quickly and successfully.

BACKGROUND OF THE INVENTION

Field of the Invention

The present invention relates to a prescription of intravenousmedication for blocking a heroin or morphine intoxication path and itsusing, and more particularly to the prescription of intravenous infusionand its using, and the intravenous medication is injected to a patientto activate the patient's liver and circulatory system, while a doctorand/or a nurse controls the timing of drug administration and the safedosage to block acute withdrawal symptoms of an acute withdrawal addictquickly and successfully by the processes of detoxication, relievingsymptoms, suppressing restlessness, and sobering.

Description of the Related Art

In medicine, heroin and morphine may be used as potent analgesic drugsfor alleviating pains caused by heart disease, trauma, surgery, etc.Since heroin and morphine have a strong addictive property, they arealso used as potent drugs. When use at an early time, a user feelshappy, peaceful and high, but fail to concentrate. The user's bodycannot function normally twelve hours after taking the drugs, andwithdrawal symptoms including tense, unable to sleep, sweating, stomachupset, pains in limbs, cramps, etc show up, and these withdrawalsymptoms continue for three to five days. The longer the user takingheroin/morphine, the longer the withdrawal symptoms last. An overdose ofheroin/morphine may cause acute poisoning with symptoms includingdrowsiness, respiratory depression, hypotension, and pupil becomingsmaller. With repeated use of heroin/morphine, high psychological andphysiological dependences occur, and the heroin/morphine addict's bodyadapts the presence of the drugs and must continue to increase theamount of dose in order to obtain the same effect. After taking thedrugs for a long term, an addict stopping taking the drugs will havewithdrawal symptoms such as drug craving, anxiety, crying, sweating,runny nose, irritability, shivering, chill, loss of appetite, diarrhea,body curl, cramp, etc, and thus it is very difficult for addicts towithdraw. It is very difficult to block the use of drugs by traditionalrehabilitation methods that adopt tranquilizers and antidepressants.

In view of the aforementioned problem that it is difficult for heroin ormorphine addicts to block the drugs, the inventor of the presentinvention conducted researches and experiments and provided a feasiblesolution to help the addicts or patients to block heroin or morphinesuccessfully.

SUMMARY OF THE INVENTION

Therefore, it is a primary objective of the present invention to providea prescription of intravenous infusion for blocking heroin or morphineaddiction.

To achieve the aforementioned objective, the present invention providesa prescription of intravenous infusion for blocking heroin or morphineaddiction, and the prescription comprises the following ingredients:Cerebrolysin, Piracetam, Cimetidine, Scopolamine Butylbromide, Nefopam,B.C Complex, Vitamin B1, Ascorbic Acid, Ketorolac, Guronsan, HyoscineButylbromide and Sukerin. Wherein, the Cerebrolysin occupies 3˜13% ofthe dosage; the Piracetam occupies 3˜13% of the dosage; the Cimetidineoccupies 3˜13% of the dosage; the Scopolamine Butylbromide occupies3˜13% of the dosage; the Nefopam occupies 3˜13% of the dosage; the B.CComplex occupies 3˜13% of the dosage; the Vitamin B1 occupies 3˜13% ofthe dosage; the Ascorbic Acid occupies 3˜13% of the dosage; theKetorolac occupies 3˜13% of the dosage; the Guronsan occupies 3˜13% ofthe dosage; the Hyoscine Butylbromide occupies 3˜13% of the dosage; andthe Sukerin occupies 3˜13% of the dosage. The prescription ofintravenous infusion can activate a patient's liver and circulatorysystem, so as to eliminate the ingredients of heroin/morphine in thepatient's body, so as to block the drugs.

Another objective of the present invention is to provide a using forblocking heroin or morphine addiction, and the treatment method includesan actual withdrawal part and an outpatient part. The acute withdrawalpart includes the following three stages:

The first stage is an acute withdrawal stage and further divided intothree phases of treatment. The first phase treatment applies 6 bottlesof the aforementioned prescription of intravenous infusion dailyaccording to a standard treatment record sheet, and clinical doctorsadds other corresponsive prescription of injection to each bottle of theprescription of intravenous infusion according to the level of apatient's clinical symptoms to primarily activate physiologicalwithdrawal. The second phase applies 6˜9 bottles of the prescription ofintravenous infusion since the patient's drug has been eliminatedquickly, the drug has dependence, and the patient's physiological andneurotransmitter system are still not recovered, and the clinicaltreatment may cause restlessness and instability, so that a prescriptionof Haloperidol and Diazepam is applied according to the level of thepatient's restlessness. The third phase treatment applies 9˜18 bottlesof the prescription of intravenous infusion and continues applying theprescription according to a standard course to complete blocking thedrugs.

The second stage is a consciousness recovery stage, wherein 2 Amp ofAkineton is added slowly into the prescription of intravenous infusionto help the patient to recover consciousness.

The third stage is a body recovery stage which completes the treatmentfor acute withdrawal of heroin damage.

In an outpatient part, the prescription of intravenous infusion,Nefopam, Sukerin, Vitamin B12, Cerebrolysin and Guronsan are applied tothe patient to achieve the effects of relieving withdrawal symptoms,assisting circulation and metabolism, and enhancing the withdrawal, soas to block the addiction successfully, and the patient's drug responsecondition can be detected by blood test to block the use of drugssuccessfully.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a table listing the composition and dosage of a prescriptionof intravenous infusion in accordance with a preferred embodiment of thepresent invention; and

FIG. 2 is a flow chart of a using in accordance with a preferredembodiment of the present invention.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The technical characteristics, contents, advantages and effects of thepresent invention will be apparent with the detailed description of apreferred embodiment accompanied with related drawings as follows.

With reference to FIG. 1 for a prescription of intravenous infusion ofthe present invention for blocking heroin or morphine addiction, theinvention focuses on the activation of a patient's liver and circulatorysystem to block the heroin or morphine addiction. The prescription ofintravenous infusion comprises the following drugs with their names anddosages:

Cerebrolysin (drug name and generic name) occupies 3˜13% of the dosageand it is a medicine for curing a patient's nervous system.

Piracetam (drug name and generic name) occupies 3˜13% of the dosage andit is a medicine for curing a patient's blood system.

Cimetidine (drug name and generic name) occupies 3˜13% of the dosage andit is a medicine for curing a patient's digestive system.

Scopolamine Butylbromide (drug name and generic name) occupies 3˜13% ofthe dosage and it is a medicine for curing a patient's peripheralnervous system as well as a parasympathetic inhibitor.

Nefopam (having a drug name “Nefopam HCL” and a generic name “Nefopam”)occupies 3˜13% of the dosage and it is a medicine for curing a patient'scentral nervous system.

B.C Complex (drug name and generic name) occupies 3˜13% of the dosageand it is a vitamin/fat-soluble vitamin complex.

Vitamin B1 (drug name and generic name) occupies 3˜13% of the dosage.

Ascorbic Acid (drug name and generic name) occupies 3˜13% of the dosage.

Ketorolac (drug name and generic name) occupies 3˜13% of the dosage andit is a non-steroidal anti-inflammatory analgesic agent for curing apatient's body pains.

Guronsan occupies 3˜13% of the dosage and it is a hepatotropic agent forcuring a patient′ drug intoxication.

Hyoscine Butylbromide (drug name and generic name) occupies 3˜13% of thedosage and it is a digestive system drug/anticonvulsant for relieving apatient's digestive track spasm.

Sukerin occupies 3˜13% of the dosage and it is used for relieving apatient's peripheral pains.

The prescription of intravenous infusion focuses on the activation of apatient's liver and circulatory system and the prescription ofintravenous infusion is applied and injected to the patient, so that theheroin/morphine drugs in the patient's body is eliminated quickly toblock addition, and different dosages may be applied according to thepatient's different symptoms, and doctors and nurses control the timingof drug administration and the safe dosage to achieve blockingaddiction.

With reference to FIG. 2 for a using of heroin or morphine addiction byusing the prescription of intravenous infusion of the present invention,the using comprises an acute withdrawal part and an outpatient part.

I. The Acute Withdrawal Part Includes the Following Stages Carried OutSequentially:

1. The first stage is an acute withdrawal stage lasting for three days,wherein 6 bottles of the prescription of intravenous infusion areapplied daily according to a standard treatment record sheet, and theprescription of intravenous infusion is applied at a speed of 4 hoursper bottle, and the first stage includes the following three usingtreatment phases:

(1) The first phase treatment (from the 4^(th) hour to the 18^(th) hour)primarily eliminates heroin/morphine in the patient's body quickly. The1^(st) to 5^(th) bottles of the prescription of intravenous infusion areapplied to the patient, and a clinical doctor adds another supplementaryprescription to the prescription of intravenous infusion according tothe level of the patient's clinical symptoms. For example, if the levelof the patient's clinical symptoms is ordinary, then 2 Amp ofHaloperidol and 1 Amp of Diazepam will be added to the prescription ofintravenous infusion; if the level of the patient's clinical symptoms ismild, then 2 Amp of Haloperidol will be added to the prescription ofintravenous infusion the prescription of intravenous infusion; and ifthe level of the patient's clinical symptoms includes severe pains allover the body, then 2 Amp of Nefopam will be slowly added to theprescription of intravenous infusion; if the level of the patient'sclinical symptoms includes moderate pains all over the body, then 1 Ampof Nefopam will be slowly added in the prescription of intravenousinfusion; if the level of the patient's clinical symptoms includesserious yawn, tears, and relief of withdrawal symptoms, then 1˜2 Amp ofSukerin will be added to the prescription of intravenous infusion, orVitamin B12 is applied to achieve the effects of improving thedetoxication, blocking the damage path of heroin/morphine, andactivating the patient's liver and relieving neuropathic pains.Cerebrolysin and Guronsan may also be supplemented to assist circulationand metabolism and enhance the physiological detoxication function.

(2) The second phase treatment (from the 18^(th) hour to the 36^(th)hour) applies the 6^(th) to 9^(th) bottles of the prescription ofintravenous infusion. After the first phase treatment, theheroin/morphine in the patient's body has been eliminated quickly, andthe patient's drug dependence is relieved quickly. However, thepatient's neurotransmitter system is still not recovered physiologicallyand cannot function normally. Since the patient is physically, mentally,and subconsciously under stress for a long time, the patient becomesrestless and unstable and has encounters disordered sleep, and therepeated unconscious restless movement will continue for 18 hours. Now,the following supplementary medicine other than the prescription ofintravenous infusion may be applied to the patient according to thelevel of the patient's restlessness. If the patient is in seriousrestlessness, then 3 Amp of Haloperidol and 2 Amp of Diazepam will beadded to the prescription of intravenous infusion; and if the patient isin moderate restlessness, then 2 Amp of Haloperidol and 2 Amp ofDiazepam will be added to the prescription of intravenous infusion.

(3) The third phase treatment (from the 36^(th) hour to the 72^(nd)hour) applies the 9^(th) to 18^(th) bottles of the prescription ofintravenous infusion to the patient to continue completing the acutewithdrawal of heroin and morphine up to 70% to 95% and block the drugdamage of heroin and morphine.

2. The second stage is a one-day consciousness recovery period (from the72^(nd) hour to the 96^(th) hour) and adds 2 Amp of Akineton (Drug Name:Akineton, and Generic Name: BIPERIDEN HCL) to the prescription ofintravenous infusion, so that the patient recovers the consciousnessnormally and quickly within 24 hours.

3. The third stage (from the 96^(th) hour to the 120^(th) hour) is abody recovery stage, and the basic functions of the patient's body enterinto the subsequent life rebuilding stage.

The present invention uses 5 days as a course to complete the acutewithdrawal treatment of blocking the drug damage of heroin.

II. Outpatient Part:

The standard period of the outpatient part is 6˜12 hours, and 3 bottlesof the prescription of intravenous infusion are used for one course, andthe prescription of intravenous infusion is injected at a speed of 2 to4 hours per bottle according to the standard treatment record sheet, andthe following prescription is applied slowly according to the patient'ssymptoms. For example, if the patient has a pain symptom, then 1˜2 Ampof Nefopam will be slowly added to the prescription of intravenousinfusion; if the patient has yawn and tears symptoms, then 1˜2 Amp ofSukerin will be slowly added to the prescription of intravenousinfusion. In addition, Vitamin B12 may be applied to the patient atappropriate time to achieve the effects of improving the detoxication,blocking the drug damage path of heroin or morphine drug damage, andactivating the patient's liver and relieve neuropathic pains.Cerebrolysin and Guronsan may also be supplemented at appropriate timeto assist the patient's circulation and metabolism and enhance thephysiological detoxication function.

The prescription of intravenous infusion and the using applying theprescription of intravenous infusion in accordance with of the presentinvention activate the patient's liver and circulatory system, anddoctors and nurses control the timing of drug administration and thesafe dosage to block the patient's addiction successfully, and bloodtest is provided for showing the patient's drug response condition, soas to block the addiction successfully.

In summation of the description above, the present invention can achievethe expected functions and objectives, and provides details to enablethe persons having ordinary skill in the art to implement the presentinvention. While the invention has been described by means of specificembodiments, numerous modifications and variations could be made theretoby those skilled in the art without departing from the scope and spiritof the invention set forth in the claims.

What is claimed is:
 1. A prescription of intravenous infusion forblocking a heroin or morphine intoxication path, comprising a pluralityof ingredients consisting of Cerebrolysin, Piracetam, Cimetidine,Scopolamine Butylbromide, Nefopam, B.C Complex, Vitamin B1, AscorbicAcid, Ketorolac, Guronsan, Hyoscine Butylbromide, and Sukerin.
 2. Theprescription of intravenous medication for blocking a heroin or morphineintoxication path according to claim 1, wherein each of the ingredientsoccupies 3˜13% of the dosage.
 3. A using of the prescription ofintravenous medication for blocking a heroin or morphine intoxicationpath according to claim 2, including an acute withdrawal part carriedout in a patient's acute withdrawal period, and the acute withdrawalpart comprising the following treatment stages: a first phase treatmentof a first stage applies the prescription of intravenous infusion to thepatient to eliminate heroin/morphine from the patient's body quickly,and a clinical doctor adds another supplementary prescription to theprescription of intravenous infusion according to the level of thepatient's clinical symptoms; a second phase treatment of the first stagecontinues applying the prescription of intravenous infusion to thepatient, and further applying a supplementary medicine other than theprescription of intravenous infusion to the patient according to thelevel of the patient's restlessness; a third phase treatment of thefirst stage continues applying the prescription of intravenous infusionto the patient to complete an acute withdrawal of heroin and morphine upto 70% to 95%, so as to block drug damage of heroin and morphine; and asecond stage, which is a consciousness recovery stage, and continuesapplying the prescription of intravenous infusion to the patient, andadds an appropriate amount of Akineton (Biperiden HCL) slowly into theprescription of intravenous infusion, so that the patient'sconsciousness recovers to normal quickly.
 4. The using according toclaim 3, wherein the first phase treatment of the first stage takesplace within the treatment period from the 4^(th) hour to the 18^(th)hour and applies the first bottle to the fifth bottle of theprescription of intravenous infusion to the patient, and then adds thesupplementary prescription consisting of Haloperidol, Diazepam, Nefopam,and Sukerin into the prescription of intravenous infusion according tothe level of patient's clinical symptoms to relieve the patient'ssymptoms.
 5. The using according to claim 4, wherein the first phasetreatment of the first stage applies the supplementary prescriptionconsisting of Vitamin B12 to the patient to improve detoxication andblock the damage path of heroin/morphine, and activate liver functionand relieve neuropathic pain, and applies the supplementary prescriptionconsisting of Cerebrolysin and Guronsan to the patient to assistcirculation and metabolism, and enhance physiological detoxicationfunction.
 6. The using according to claim 3, wherein the second phasetreatment of the first stage takes place within the treatment periodfrom the 18^(th) hour to 36^(th) hour and applies the 6^(th) bottle tothe 9^(th) bottle of the prescription of intravenous infusion to thepatient, and further applies the supplementary medicine other than theprescription of intravenous infusion to the patient according to thelevel of the patient's restlessness, and the supplementary medicineincludes Haloperidol and Diazepam.
 7. The using according to claim 3,wherein the third phase treatment of the first stage takes place withinthe treatment period from the 36^(th) hour to the 72^(nd) hour andapplies the 9^(th) bottle to the 18^(th) bottle of the prescription ofintravenous infusion to the patient.
 8. The using according to claim 3,wherein the second stage takes place within the treatment period fromthe 72^(nd) hour to the 96^(th) hour.
 9. The using according to claim 3,further comprising an outpatient part with a standard period of 6˜12hours, and 3 bottles of the prescription of intravenous infusion beingused as a course, and the prescription of intravenous infusion beinginjected at a speed of 2˜4 hours per bottle according to the standardtreatment record sheet, and the supplementary prescription together withthe prescription of the intravenous infusion being injected slowly byintravenous infusion according to the patient's symptoms.
 10. The usingaccording to claim 9, wherein the outpatient part adds the supplementarymedicine consisting of Nefopam and Sukerin into the prescription ofintravenous infusion according to the patient's symptoms, and suppliesVitamin B12, Cerebrolysin and Guronsan to the patient.
 11. A using ofthe prescription of intravenous medication for blocking a heroin ormorphine intoxication path according to claim 1, including an acutewithdrawal part carried out in a patient's acute withdrawal period, andthe acute withdrawal part comprising the following treatment stages: afirst phase treatment of a first stage applies the prescription ofintravenous infusion to the patient to eliminate heroin/morphine fromthe patient's body quickly, and a clinical doctor adds anothersupplementary prescription to the prescription of intravenous infusionaccording to the level of the patient's clinical symptoms; a secondphase treatment of the first stage continues applying the prescriptionof intravenous infusion to the patient, and further applying asupplementary medicine other than the prescription of intravenousinfusion to the patient according to the level of the patient'srestlessness; a third phase treatment of the first stage continuesapplying the prescription of intravenous infusion to the patient tocomplete an acute withdrawal of heroin and morphine up to 70% to 95%, soas to block drug damage of heroin and morphine; and a second stage,which is a consciousness recovery stage, and continues applying theprescription of intravenous infusion to the patient, and adds anappropriate amount of Akineton (Biperiden HCL) slowly into theprescription of intravenous infusion, so that the patient'sconsciousness recovers to normal quickly.
 12. The using according toclaim 11, wherein the first phase treatment of the first stage takesplace within the treatment period from the 4^(th) hour to the 18^(th)hour and applies the first bottle to the fifth bottle of theprescription of intravenous infusion to the patient, and then adds thesupplementary prescription consisting of Haloperidol, Diazepam, Nefopam,and Sukerin into the prescription of intravenous infusion according tothe level of patient's clinical symptoms to relieve the patient'ssymptoms.
 13. The using according to claim 12, wherein the first phasetreatment of the first stage applies the supplementary prescriptionconsisting of Vitamin B12 to the patient to improve detoxication andblock the damage path of heroin/morphine, and activate liver functionand relieve neuropathic pain, and applies the supplementary prescriptionconsisting of Cerebrolysin and Guronsan to the patient to assistcirculation and metabolism, and enhance physiological detoxicationfunction.
 14. The using according to claim 11, wherein the second phasetreatment of the first stage takes place within the treatment periodfrom the 18^(th) hour to 36^(th) hour and applies the 6^(th) bottle tothe 9^(th) bottle of the prescription of intravenous infusion to thepatient, and further applies the supplementary medicine other than theprescription of intravenous infusion to the patient according to thelevel of the patient's restlessness, and the supplementary medicineincludes Haloperidol and Diazepam.
 15. The using according to claim 11,wherein the third phase treatment of the first stage takes place withinthe treatment period from the 36^(th) hour to the 72^(nd) hour andapplies the 9^(th) bottle to the 18^(th) bottle of the prescription ofintravenous infusion to the patient.
 16. The using according to claim11, wherein the second stage takes place within the treatment periodfrom the 72^(nd) hour to the 96^(th) hour.
 17. The using according toclaim 11, further comprising an outpatient part with a standard periodof 6˜12 hours, and 3 bottles of the prescription of intravenous infusionbeing used as a course, and the prescription of intravenous infusionbeing injected at a speed of 2˜4 hours per bottle according to thestandard treatment record sheet, and the supplementary prescriptiontogether with the prescription of the intravenous infusion beinginjected slowly by intravenous infusion according to the patient'ssymptoms.
 18. The using according to claim 17, wherein the outpatientpart adds the supplementary medicine consisting of Nefopam and Sukerininto the prescription of intravenous infusion according to the patient'ssymptoms, and supplies Vitamin B12, Cerebrolysin and Guronsan to thepatient.